Week in Review: BeiGene Plans $2.5 Billion IPO on Shanghai Star Exchange

Deals and Financings   BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion, adding to its NASDAQ and HK listings; Shanghai Antengene, a three-year old oncology company, completed a $340 million IPO in Hong Kong to develop its portfolio of 12 cancer therapies; RecBio, a Taizhou company that makes genetically engineered biotech vaccines for major diseases, completed a $227 million Series B round; D3 Bio, a Shanghai startup, raised $200 million in a Series A financing from well-known China investors to develop precision medicines; Shanghai Newsoara Biopharma partnered with Singapore 's AUM Biosciences to co-develop up to six oncology drugs in China in a deal worth up to $135 million; GenScience Pharma announced a $132 million agreement to acquire China rights to two long-acting prostate cancer therapies from Taiwan 's Foresee Pharma; Wuxi Biortus Biosciences, a drug discovery CRO, closed a $15 million Series A financing to build a cryogenic electron microscopy innovation center; ChinaBio® Exclusive   The management of LianBio, a Princeton-Shanghai company, discuss their $70 million partnership with Pfizer to co-develop novel pharmaceuticals in Greater China; COVID-19 Pandemic   WuXi Biologics is working on 10 neutralizing antibodies and one vaccine from clients for COVID-19, while Sinopharm said three unapproved China vaccines have been administered to one million people in China; Trials and Approvals   Beijing 's BeiGene announced China approval to market Xgeva® for patients with bone metastases from solid tumors or multiple myeloma; Alphamab Oncology and 3D Medicines filed a China NDA for their partnered anti-PD-L1 therapy as a treatment for MSI-H/dMMR cancer; Suzhou Innovent reported its bi-specific fusion protein was effective in patients with neovascular age-related macular degeneration in a Phase I trial.   Stock Symbols: (NSDQ: BGNE; HK: 06160) (HK: 6996) (TWO: 6576) (HK: 2269) (HK: 9966) (HK: 01801) Share this with colleagues: // //